3
Jul 2025
Shaping the future of lab automation through AI and robotics
Discover how Chemspeed is revolutionizing lab automation with AI-driven workflows, modular robotics, and more

Increasing and changing demands concerning the health of populations and limited resources require our health care organizations and systems to rethink their sustainability. To achieve objectives, such as improved healthcare quality, health outcomes, efficiency and staff satisfaction, we support our clients in making evidence-based decisions. With tailor-made research projects, we provide insights into what works, for whom, at what cost, and under what circumstances. Based on your challenge, we can support you by:
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
3
Jul 2025
Discover how Chemspeed is revolutionizing lab automation with AI-driven workflows, modular robotics, and more
3
Jul 2025
Women who see themselves as having lower social status are more likely than other people to show early signs of heart stress linked to future disease risk, according to a new study led by researchers at McGill and Concordia universities.
3
Jul 2025
In August 2024, the World Health Organization declared a second "Public Health Emergency of International Concern" for mpox.
3
Jul 2025
A new study by investigators from Europe, including the Netherlands and the United Kingdom (UK), has shed light on significant ethical, administrative, regulatory, and logistical (EARL) hurdles in delivering multinational randomized clinical trials.